Sanofi (SAN.PA,SNY), a French pharmaceutical and healthcare company, on Thursday announced that the Board of Directors had decided not to renew the director mandate of Chief Executive Officer Paul Hudson, with his last day set for February 17, at the close of business.
Belén Garijo has been appointed Chief Executive Officer and will assume the role at the end of the Group's Annual General Meeting on April 29.
The company said that the shareholders will vote on her appointment to the Board, along with a proposed amendment to the articles of association to raise the CEO age limit required for her election.
Olivier Charmeil, Executive Vice President, General Medicines, will serve as Interim Chief Executive Officer during the transition period.
Garijo previously served as Chief Executive Officer of Merck KGaA since 2021 and was a member of Sanofi's Executive Committee for 15 years, including as Vice President of Pharmaceutical Operations for Europe and Canada.
On Wednesday, Sanofi closed trading 0.44% higher at EUR 82.56 on the Paris Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.